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Abstract The principal antioxidant in human LDL, a-tocophe- 
rol, is converted to the a-tocopheroxyl radical after reaction with 
peroxyl radicals or Cu 2+, and, if it does not terminate with per- 
oxyl radicals, could initiate lipid peroxidation; a phenomenon 
called 'tocopherol mediated peroxidation'. Only in the presence 
of Cn 2+ and low levels of lipid hydroperoxides was an o~-tocophe- 
rol dependent decrease in the resistance of LDL to oxidation 
detected. This suggests that toeopherol mediated peroxidation 
will probably not contribute significantly as a pro-oxidant process 
in those individuals most at risk of developing atherosclerosis 
through an oxidative mechanism. 
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1. Introduction 
The modification of low density lipoprotein (LDL) through 
an oxidative mechanism ay be one of the initial events leading 
to the development of an atherosclerotic lesion [1-3]. The evi- 
dence in favour of this hypothesis has been extensively reviewed 
[4-6] and its possible relevance to humans emphasised by the 
findings of recent epidemiological studies that showed that 
increased intake of antioxidant vitamins may decrease the risk 
of developing coronary heart disease [7,8]. Of particular interest 
is the endogenous lipid soluble chain breaking antioxidant 
c~-tocopherol which appears to be the major defence against 
oxidative damage in the LDL particle [9-14]. In support of this 
role for ~-tocopherol it has been demonstrated that dietary 
supplementation leads to increased levels in LDL and, for a 
given individual, is invariably associated with an increased re- 
sistance to oxidation promoted ex vivo by pro-oxidants such 
as copper [10-12]. However, many of these studies have also 
revealed that the effectiveness of ~-tocopherol as an antioxi- 
dant in LDL can vary markedly between individuals when Cu 2+ 
is used as a pro-oxidant [10-15]. In contrast, this variation is 
not seen when a transition metal independent process, such as 
an azo initiator, is used to promote LDL oxidation [13]. 
Recent studies of the antioxidant action of ~-tocopherol in
LDL have revealed an intriguing propensity of this antioxidant 
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to promote lipid peroxidation, particularly when the flux of 
peroxyl radicals, which ~-tocopherol scavenges, is low [15--18]. 
The suggested mechanism for the pro-oxidant reaction of the 
~-tocopheroxyl radical is the initiation of lipid peroxidation 
through abstraction of an H atom from an unsaturated fatty 
acid [16-19]. The rate of this reaction is, however, in the order 
of 0.12 M -1 .s -l, which is approximately 1 x 109 times slower 
than the estimated rate of reaction of the e-tocopheroxyl radi- 
cal with peroxyl radicals [18-21]. This result suggests that only 
under conditions where the flux of peroxyl radicals is exceed- 
ingly small will tocopherol mediated peroxidation occur. Ac- 
cordingly, these reactions have been investigated under condi- 
tions where the rate of LDL oxidation is either negligible or 
slow using non-physiological oxidants uch as the peroxyl rad- 
ical generating azo initiators [17]. However, in human athero- 
sclerotic lesions, lipid decomposition products such as 4-hy- 
droxynonenal, malondialdehyde and fragmented LDL protein 
have been detected, all indicating at least a transitory state 
where extensive lipid decomposition has occurred [2,3]. Under 
these conditions the termination reaction of the ~-tocopheroxyl 
radical with peroxyl radicals will negate or diminish its poten- 
tial for pro-oxidant reactions. An examination of the behaviour 
of ~-tocopherol under different conditions of peroxyl radical 
flux is required before we can assess the importance of its 
pro-oxidant reactions during LDL oxidation which, at present, 
remain unclear. 
The copper and haem protein dependent oxidation of both 
lipids and LDL are thought o be dependent on the presence 
of pre-formed, or 'seeding', lipid hydroperoxides and may be 
analogous to the oxidative processes which occur in the athero- 
sclerotic lesion itself [2,3,14,22-27]. Accordingly, we have pro- 
posed that variation in the levels of these peroxides between 
LDL isolated from different individuals may, in part, explain 
the observed variable fficacy of ~-tocopherol asan antioxidant 
in human LDL; recent studies support this view [13,14,26]. 
Other possibilities include contributions from ubiquinol, LDL 
protein and variations in fatty acid composition [5,14,28]. 
In the present study the interactions between ~-tocopherol, 
lipid hydroperoxides, and transition metals in LDL have been 
investigated using Cu 2÷ and the haem protein metMb as pro- 
oxidants. It has been shown that ct-tocopherol reacts directly 
with Cu 2÷ in LDL [19], with the concomitant formation of the 
~-tocopheroxyl radical and Cu ÷ [18,19]. This could then result 
in a copper and ~-tocopherol dependent pro-oxidant reaction 
which does not require lipid hydroperoxides. In this respect we 
have found that metMb is an important control since it does 
not react with ct-tocopherol but shares with Cu 2÷ a requirement 
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for lipid peroxides for the promotion of oxidation in LDL 
[24,26]. The protocols chosen have allowed us to explore the 
pro and antioxidant effects of ~-tocopherol under varying con- 
ditions of peroxyl radical flux which we have achieved by in- 
creasing the peroxide content by supplementation with 13- 
HPODE and decreasing it with the compound ebselen 
[24,26,32]. 
2. Materials and methods 
2.1. Isolation and characterisation f LDL 
Human LDL was isolated from the plasma of healthy donors by 
differential centrifugation using the method escribed previously [26]. 
In all, five separate LDL preparations were used in this study, with 
three plasma samples from different donors being supplemented with 
~-tocopherol using the protocol described in [11,13]. In brief, the 
plasma was supplemented with ~-toeopherol t  give a range of concen- 
trations (0-1.2 mM in 1% ethanol v/v) and the LDL then isolated from 
the plasma s before [26]. Typically, this resulted in ~-toeopherol levels 
of 10~0 nmol/mg LDL protein. After dialysis against Ca>/MgZ+-free 
phosphate buffered saline (PBS) containing 10/aM EDTA, the LDL 
was sterilised by filtration through a 0.2/aM pore size filter and stored 
at 4°C before use. The LDL protein concentration was determined 
using bovine serum albumin as a standard and the BCA protein assay 
reagent (Pierce). The ~-tocopherol in LDL was extracted into heptane 
and the content determined by HPLC [10]. 
2.2. Measurement of the oxidisability of LDL 
Oxidisability of LDL samples initiated by CuSO4 or metMb was 
determined spectrophotometrically (234 nm) as described previously 
and the lag phase was measured [30]. The concentrations ofmetMb and 
CuSO4 selected for these xperiments were determined from prior deter- 
mination of the concentration dependence of the oxidant in oxidising 
LDL. In both cases it was a saturable process with 30-50/aM CuSO4 
and 10-20/aM metMb yielding the maximum rate of oxidation and 
minimum period for the lag phase (data not shown). Where possible, 
saturating levels of these oxidants were used. In those experiments 
where AAPH was used to initiate lipid peroxidation a concentration f
1 mM was used as described in [17]. All experiments were performed 
in duplicate and the data presented as the means of these values. Typical 
variation between experiments was between 3-7% for both c~-tocophe- 
rol measurements and determination f 'lag phase'. Ebselen (0.1-5/tM) 
and 13-HPODE (5/aM) were used to modulate the initial concentration 
of lipid hydroperoxide in LDL and were added as ethanolic solutions 
M. Iwatsuki et al./FEBS Letters 360 (1995) 271-276 
(final concentration maintained at 1% v/v). When ebseler~ was added, 
LDL was treated for 30 rain at room temperature b fore the addition 
of other oxidants [23,31,32]. The remaining ebselen was not removed 
from the LDL. 
2.3. Reagents 
AAPH was purchased from Polyseiences (Warrington, PA, USA) 
and ~-tocopherol and metMb from Sigma. 13-HPODE was obtained 
from Cascade and used without further purification. Ebselen was the 
generous gift of the Astra pharmaceutical company, Sweden. 
3. Results 
3.1. Oxidation of ~-tocopherol in homogeneous solution and in 
ebselen treated LDL by Cu 2+ and metMb 
The addition of Cu e+ to ~-tocopherol in 1% ethanol/PBS 
resulted in its rapid oxidation, whereas metMb was completely 
without effect (Fig. la). When either pro-oxidant was added to 
LDL, depletion of ~-tocopherol ccurred (Fig. lb), confirming 
the results from other laboratories [30]. Interestingly, after 
treatment with the compound ebselen, which removes lipid 
hydroperoxides from LDL [25,31,32], the metMb dependent 
oxidation of ~-tocopherol was inhibited whereas the Cu 2+ de- 
pendent oxidation of ~-tocopherol was still observed, albeit at 
a considerably lower rate (Fig. lc). 
3.2. Depletion of o~-tocopherol in LDL after treatment with 
Cu e+, metMb or AAPH 
To test the effects of increasing ~-tocopherol content on the 
rate of  oxidation with the pro-oxidants Cu 2+, metMb or AAPH,  
samples of plasma from single donors were supplemented with 
this antioxidant and the LDL isolated [11,13]. The LDL was 
then exposed to the pro-oxidants Cu 2+, metMb and AAPH and 
the rate of ~-tocopherol xidation measured. Results typical of 
one of three independent experiments with different LDL prep- 
arations are shown in Fig. 2. It is evident hat only in the case 
of Cu 2+ (Fig. 2b) did the rate of  oxidation show any variation 
with increasing concentration of ~z-tocopherol. In marked con- 
trast, the rate of ~-tocopherol xidation with either the peroxyl 
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Fig. 1. Reaction of c~-tocopherol with metMb and Cu 2+ in solution and in LDL. MetMb (©) or Cu 2+ (r~) was incubated at 37°C in air equilibrated 
buffer for the times indicated before analysis by HPLC. (a) c~-Tocopherol (2/aM) dissolved in 1% ethanol (v/v PBS) was incubated with either 10/aM 
Cu 2+ or 50/aM metMb. (b) LDL (125/ag/ml) was incubated with either 50/aM Cu 2÷ or 50/aM metMb. (c) LDL pre-incubated with ebselen (10/aM) 
for 30 min was incubated with Cu 2÷ or metMb as described in panel b. Each point represents the mean of experiments performed in 
duplicate. 
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Fig. 2. Depletion of e-tocopherol in LDL with Cu 2+, metMb and AAPH. LDL (125/~g/ml) was prepared with 33 (zx), 31 (tz), 27 (e) or 12 (o) nmol 
~-tocopherol/mg LDL and incubated with 50/.tM metMb (a), 50 ¢tM Cu 2+ (b) or 1 mM AAPH (c) before samples were taken for e-tocopherol 
measurement, by HPLC, at the times indicated. Each point represents he mean of experiments performed in duplicate. 
radical generator AAPH or the metMb dependent decomposi- 
tion of lipid hydroperoxides, was constant (Fig. 2a and c, re- 
spectively). 
We then determined the rate of c~-tocopherol depletion for 
each sequential 5 min period for both Cu 2÷ and metMb as 
oxidants and the results for both sets of data are shown in Fig. 
3. It is clear that while the rate of oxidation of ~-tocopherol 
with Cu > increases as a direct function of the ~-tocopherol 
concentration during the course of the reaction (Fig. 3b), the 
rate of oxidation with metMb as a pro-oxidant isconstant (Fig. 
3a). Furthermore, within experimental error the data derived 
from all four LDL preparations lies on the same line (Fig. 3b), 
supporting our underlying assumption that, in all respects other 
than ~-tocopherol content, these LDL preparations were essen- 
tially similar. 
3.3. The resistance of LDL to oxidation: the role of lipid 
hydroperoxides and o:-tocopherol 
In the experiments conducted so far we have demonstrated 
that the rate of oxidation of c~-tocopherol in LDL, when ex- 
posed to Cu 2+, increases with increasing antioxidant concentra- 
tion, implicating a key role for a direct reaction with Cu 2÷ under 
these conditions. This reaction involves the oxidation of 
c~-tocopherol yielding the c~-tocopheroxyl radical [19]. This 
species is still capable of scavenging one peroxyl radical per 
mole, which would then decrease by half the total amount of 
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Fig. 3. Rate of loss of a-tocopherol as a function of a-tocopherol concentration with metMb and Cu 2÷ as oxidants. The rate of ~-tocopherol depletion 
over each sequential 5 rain period was calculated from the data shown in Fig. 2 for both oxidation by metMb (a) and Cu 2÷ (b), and was plotted as 
a function of the c~-tocopherol concentration at the beginning of each 5 rain period of the experiment. LDL (125 pg/ml) was prepared with 33 (z~), 
31 (D), 27 (e) or 12 (o) nmol c~-tocopherol/mg LDL. 
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Fig. 4. Oxidative resistance of LDL, supplemented with lipid hydroper- 
oxides or treated with ebselen, to oxidation promoted by metMb or 
Cu 2+. The endogenous lipid hydroperoxide content of normal LDL ([z) 
was manipulated by either the addition of 5/zM 13-HPODE (zx) or 
0.1/zM (e), 2/IM (A), 5/zM (o) ebselen and either 10/zM metMb (a) 
or 50/zM Cu 2+ (b) used as pro-oxidants. Resistance to oxidation was 
measured by estimating the 'lag phase' as described in [1]. Each point 
represents he mean of duplicate measurements. 
~-tocopherol able to act as an antioxidant. However, if the 
~-tocopheroxyl radical was also able to initiate lipid peroxida- 
tion [16,17] then a pro-oxidant effect may also be observed. To 
test for this possibility we examined the effect of increasing lipid 
hydroperoxide levels by supplementation with 13-HPODE 
[24,26] or decreasing them by pre-treatment with the synthetic 
glutathione peroxidase mimic ebselen [25,32] and then subject- 
ing LDL supplemented with different levels of ~-tocopherol to
oxidation with either metMb or Cu >. 
In the case of metMb, which does not oxidise ~-tocopherol 
directly (Fig. la), increasing levels of ~-tocopherol resulted in 
greater esistance to oxidation whether the peroxide content of 
LDL was increased above control evels or decreased by treat- 
ment with ebselen (Fig. 4a). With copper as the pro-oxidant, 
treatment with ebselen increased and supplementation with 
13-HPODE decreased the resistance to oxidation [26,32]. How- 
ever, in marked contrast to the results with metMb, increasing 
~-tocopherol levels in the presence of ebselen were associated 
with decreased resistance to oxidation, that is, a shorter lag 
phase (Fig. 4b). The pro-oxidant effect was apparently depend- 
ent upon the lipid hydroperoxide content and reverted to an 
antioxidant response when the LDL was supplemented with 
13-HPODE. 
4. Discussion 
The copper or haem protein dependent oxidation of LDL is 
thought o require the presence of pre-formed 'seeding perox- 
ides' in the particle before oxidation will occur [24-26]. Al- 
though the origin of these peroxides remains uncertain, it is 
apparent from recent studies that they are formed in vivo [33]. 
These results are consistent with the finding that the resistance 
of LDL oxidation to copper is idiosyncratic with respect to the 
donor, even when LDL is prepared under identical conditions, 
and this can be partially ascribed to variation in the content of 
endogenous lipid hydroperoxides and ~-tocopherol [11,13,14]. 
Indeed, the decreased resistance of LDL to copper dependent 
oxidation found in groups of subjects at greater isk from 
developing atherosclerosis supports the further extension of 
this idea to include the possibility that readily oxidised LDL 
may be pro-atherogenic [34-36]. 
It has been shown in a number of studies that dietary supple- 
mentation with ~-tocopherol results in the incorporation of this 
lipophilic antioxidant into LDL and an associated increased 
resistance to oxidation when promoted by Cu 2+ [11,12,37]. Al- 
though this is a plausible approach to suppressing the develop- 
ment of atherosclerosis it must be tempered by the observation 
that under some circumstances c~-tocopherol may initiate lipid 
peroxidation (16-18). 
In the present study we have addressed this issue by examin- 
ing the resistance of LDL to oxidation promoted by met Mb 
and Cu 2+, both of which require lipid peroxides to promote 
lipid peroxidation i LDL, and exploited this property to assess 
the antioxidant or pro-oxidant properties of e-tocopherol. Fur- 
thermore, a comparison of the behaviour of these two pro- 
oxidants may be particularly informative since Cu 2+ but not 
met Mb (Fig. 1) oxidises c~-tocopherol with the associated for- 
mation of Cu ÷ and the ~-tocopheroxyl radical [19]. This pro- 
vides an opportunity to generate ~-tocopheroxyl radicals under 
conditions of high and low lipid hydroperoxide content. 
In the first series of experiments we measured the rate of 
~-tocopherol depletion with both Cu 2+ and metMb and com- 
pared this with the azo-initiator AAPH, which generates a
constant flux of peroxyl radicals which enter the lipophilic 
environment and do not react directly with a-tocopherol under 
these conditions. The rate of depletion of ~-tocopherol with 
AAPH and metMb is both independent ofthe initial concentra- 
tion of antioxidant and linear, again demonstrating the lack of 
a direct reaction (Fig. 2a,c). This form of progress curve is 
consistent with a progressively increasing concentration ofper- 
oxyl radicals leading to a constant rate of depletion of ~-toco- 
pherol, even though its concentration is decreasing throughout 
the reaction. When Cu 2+, a pro-oxidant, is used, the rate of 
depletion of ~-tocopherol increases with the concentration of 
antioxidant (Figs. 2b and 3b), and the reaction proceeds even 
in the presence of ebselen (Fig. lc). We have shown previously 
that this effect is simply explained by the direct reduction of 
copper by ~-tocopherol, and it follows that, under the condi- 
tions we have used, those samples of LDL containing supple- 
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mented ~,tQcopfierol will contain higher levels of the c~-toco- 
pheroxyl radical [19]. 
In the second series of experiments we examined the effects 
of these treatments on the resistance of LDL to oxidation with 
either enhanced or decreased levels of lipid hydroperoxides. To
decrease lipid hydroperoxide l vels in LDL we used ebselen, 
which has previously been shown to act in LDL solely by 
metabolising lipid hydroperoxides to their corresponding alco- 
hols, which are unable to sustain a transition metal dependent 
oxidation of LDL [26,32]. We did not remove ebselen from 
LDL since this was not essential for the purpose of testing the 
role of seeding peroxides, and in so doing we avoided poten- 
tially pro-oxidant procedures such as extended ialysis. When 
metMb was used as the oxidant he lowest concentration (0.1 
/aM) of ebselen used to treat LDL inhibited lipid peroxidation 
(Fig. 4a) and with higher concentrations (2-5/tM) it was com- 
pletely suppressed (result not shown). The endogenous lipid 
hydroperoxides present in human LDL are probably in the 
region of 6-12 pmol/mg LDL protein which is at the limit of 
detection for most analytical procedures including chemilumi- 
nescence (33). We were also unable to detect lipid peroxides in 
untreated LDL and so monitor their decrease on ebselen treat- 
ment. Nevertheless, previous tudies upport both the specific- 
ity of action of the compound in metabolising lipid hydroperox- 
ides and its ability to inhibit he increase in lipid hydroperoxides 
which occurs during the transition metal dependent oxidation 
of LDL (32,38). 
To increase lipid hydroperoxide levels we used supplementa- 
tion with 13-HPODE which we have previously shown en- 
hances the rate of both metMb and Cu 2÷ oxidation (24,26). The 
data shown in Fig. 4 suggest that where ~-tocopheroxyl radicals 
are generated as a consequence scavenging peroxyl radicals, in 
this example through the action of metMb on lipid peroxides, 
then it behaves as an antioxidant and increasing concentrations 
predictably increase the resistance of the lipoprotein to oxida- 
tion. The efficacy of ebselen in inhibiting LDL oxidation pro- 
moted by Cu 2÷ was significantly ess when compared to metMb 
(Fig. 4). For example, after treatment with 2 or 5/.tM ebselen, 
and in contrast to metMb, Cu 2+ was still capable of promoting 
lipid peroxidation (Fig. 4b). Since we can assume that the con- 
centration of lipid hydroperoxides is negligible (ebselen is in a 
100-5000 molar excess to the probable endogenous levels) 
under these conditions then it appears that ~-tocopheroxyl 
radicals formed from the reaction with Cu 2+ are initiating lipid 
peroxidation resulting in the paradoxical effect of decreasing 
the resistance of LDL to oxidation as the concentration of 
~-tocopherol increases (Fig. 4b). It is unlikely that Cu +, which 
is also formed in this reaction with ~-tocopherol, is acting as 
a pro-oxidant since it also requires lipid hydroperoxides to form 
alkoxyl radicals. Furthermore, recent studies suggest that 
alkoxyl radicals are similar to peroxyl radicals in their efficiency 
of propagating lipid peroxidation since they undergo rapid 
internal rearrangement reactions [39]. An interesting conclu- 
sion from this study must be that while metMb may have an 
absolute requirement for lipid hydroperoxides in promoting 
LDL oxidation, this is clearly not the case for Cu 2÷. It would 
appear that in the absence of lipid hydroperoxides, Cu 2÷ may 
promote oxidation in an ~-tocopherol dependent process which 
probably involves the c~-tocopheroxyl radical. 
Whether these reactions are relevant to human atherosclero- 
sis is of course open to argument. The insertion of seeding 
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peroxides into the LDL particle could proceed through a reac- 
tion dependent upon 15-1ipoxygenase [40,41]. The relevance of 
copper dependent oxidation to atherosclerosis is also debatable 
but the recent finding of redox active transition metals in 
human atherosclerotic lesions and the peroxynitrite dependent 
release of copper from caeruloplasmin, the major extracellular 
copper containing protein, provide the evidence for its presence 
in lesions and a possible mechanism for its release [27,42]. 
However, it is important o note that tocopherol mediated 
peroxidation was only detectable in samples of LDL with low 
lipid hydroperoxide content and a high intrinsic resistance to 
oxidation (Fig. 4b). This suggests that, at worst, dietary supple- 
mentation with ~-tocopherol would have little or no effect on 
the resistance of LDL to oxidation in those individuals proba- 
bly at least risk of developing atherosclerosis through an oxida- 
tive mechanism. 
References 
[1] Brown, M.S. and Goldstein. J.L. (1983) Annu. Rev. Biochem. 52, 
223 261. 
[2] Yla-Hertuala, S., Palinski, W., Rosenfield, M.E., Parthasarathy, 
S., T.E. Carew, S., Butler, S., Witztum, J.L. and Steinberg, D. 
(1989) J. Clin. Invest. 84, 1086-1099. 
[3] Palinski, W., Rosenfield, M.E., Yla-Hertuala, S., Gurtner, G.C., 
Socher, S.S, Butler, S.W., Parthasarathy, S. , Carew, T.E., 
Steinberg, D. and Witztum. J.L. (1989) Proc. Natl. Acad. Sci. 86, 
1372- 1376. 
[4] Witztum J.I. and Steinberg. D. (1991) J. Clin. Invst. 88, 1785-1792. 
[5] Esterbauer, H., Gebicki, J., Puhl, H and Jurgens, G. (1993) Free 
Rad. Biol. Med. 13, 341 390. 
[6] Darley-Usmar, V.M. and Hassall. D.G. (1993) in: Immunophar- 
macology of the Heart (Curtis, M., ed.) pp. 43-51, Academic Press, 
London. 
[7] Rimm, E.B., Stampfer, M.J., Ascherio, A., Giovannucci, E., 
Coldits, G.A. and Willett. W.C. (1993) N. Engl. J. Med. 328, 
1450-1456. 
[8] Stampfer, K.J., C.H. Hennekens, J.E. Manson, G.A. Colditz, B. 
Rosner and W.C. Willett. (1993) N. Engl. J. Med. 328, 1444-1449. 
[9] Sato, K., Niki, E. and Shimasaki. H. (1990) Arch. Biochem. Bio- 
phys. 279, 402-405. 
[10] Jessup, W., Rankin, S.M., De Walley, C.V., Hoult, J.R. and 
Leake. D.S. (1990) Biochem. J. 265, 399-405. 
[11] Dieber-Rotheneder, M., Puhl, H., Waeg, G. Striegl, G. and 
Esterbauer, H. (1991) J. Lipid Res. 32, 1325-1332. 
[12] Jialal, I. and Grundy. S.M. (1992) J. Lipid Res. 33, 899-906. 
[13] Smith, D., O'Leary, V.J. and Darley-Usmar. V.M. (1993) Bio- 
chem. Pharmacol. 45, 2195-2201. 
[14] Frei, B. and Gaziano. J.M. (1993) Lipid Res. 34, 2135-2145. 
[15] Kontush, A., Hubner, C. , Finckh, B., Kohlshutter, A. and 
Beisiegel. U. (1994) FEBS Letts. 341, 69-73. 
[16] Bowry, V.W. and Stocker. R. (1993) J. Am. Chem. Soc. 115, 
6029-6044. 
[17] Bowry, V.W., Ingold, K.U. and Stocker. R. (1992) Biochem. J. 
288, 341-344. 
[18] Maiorino, M., Zamburlini, A.  Roveri, A.  and Ursuni. F. (1993) 
FEBS Lett. 330, 174-176. 
[19] Yoshida, Y., Tsuchiya, J. and Niki. E. (1994) Biochim. Biophys. 
Acta. 1200, 85-92. 
[20] Niki, E., Saito,T., Kawakami, A. and Kamiya, Y. (1984) J. Biol. 
Chem. 259, 4177-4182. 
[21] Mukai, K., Morimoto, H., Okauchi, Y. and Nagoaka, S., (1993) 
Lipids 28, 753-756. 
[22] Yoshida, Y. and Niki. E. (1992) Arch. Biochem. Biophys. 295, 
107-114. 
[23] Noguchi, N., Yoshida,Y. Kaneda, H., Yamamoto, Y. and Niki. 
E. (1992) Biochem. Pharmacol. 44, 39-44. 
[24] Hogg. N., C. Rice-Evans, Darley-Usmar, V.M., Wilson, M.T., 
Paganga, G. and Bourne, L. (1994) Arch Biochem. Biophys. 314, 
39-44. 
276 
[25] Thomas, C, . E. and Jackson. R.L., (1991) J. Pharmacol. Exp. 
Ther. 256, 1182 1188. 
[26] O'Leary, V.J., Darley-Usmar, V.M., Russell, L. J. and Stone. D. 
(1992) Biochem. J. 282, 631-634. 
[27] Smith, C., Mitchinson, M.J., Aruoma, O. and Halliwell. B. (1992) 
Biochem. J. 286, 901 905. 
[28] Reaven, P., Parthasarathy, S. Grasse, B.J., Miller, E., Alonazan, 
F., Mattson, F.H., Khoo, J.C., Steinberg, D. and Witztum, J.L. 
(1991) Am. J. Clin. Nutr. 54, 701-706. 
[29] Chung, B.H., Wilkinson, T., Geer, J.C. and Segrest. J.P. (1980) 
J. Lipid Res. 21,284-291. 
[30] Esterbauer, H., Striegl, G. Puhl, H. and Rotheneder. M. (1989) 
Free Rad. Res. Commun. 6, 67-75. 
[31] Sattler, W., Mariorino, M. and Stocker, R. (1994) Arch. Biochem. 
Biophys. 309, 214-221. 
[32] Noguchi, N., Gotoh, N. and Niki, E. (1994) Biochim. Biophys. 
Acta 1213, 176-182. 
[33] Thomas, J.P, Kalyanaraman, B. and Girotti, A.W., Arch. Bio- 
chem. Biophys. (1994) 315, 244-254. 
[34] Regnstrom, J. Nilsson, J., Tornvall, P., Landou, C. and Hamsten, 
A. (1992) Lancet 339, 1183-1186. 
[36] 
[37] 
[381 
[39] 
[401 
[41] 
M. lwatsuki et al. IFEBS Letters 360 (1995) 271-276 
[35] Maggi, E., Bellazzi, R., Falaschi, F., Frattoni, "A,~ Perani, G., 
Finardi, G., Gazo., A., Nai, M., Romanini, D. and Bellomo, G. 
(1994) Kid. Int. 45, 876-883. 
Chait, A., Brazg, R.L., Tribble, D.L. and Krauss, R.M. (1993) 
Am. J. Med. 94, 350-356. 
Reaven, ED., Khouw, A., Beltz, W.F., Parthasarathy, S. and 
Witztum, J.L. (1993) Arterioscl. Thromb. 13, 590-600. 
Maiorino, M., Roveri, A. and Ursini, F. (1992) Arch. Biochem. 
Biophys. 295, 404-409. 
Wilcox, A.L. and Marnett, L.J. (1993) Chem. Res. Toxicol. 6, 
413416. 
Rankin, S., Parthasarathy, S. and Steinberg. D. (1991) J. Lipid 
Res. 32, 449456. 
Yla-Hertuala, S., Rosenfeld, M.E., Parthasarathy, S.  Glass, C.K., 
Sigal, E. , Witztum, J. L. and Steinberg. D. (1990) Proc. Natl. 
Acad. Sci. USA, 87, 6959-6963. 
[42] Swain, J.A., Darley-Usmar, V.M. and Gutteridge, J.M.C. (1994) 
FEBS Lett. 342, 49-52. 
